CVRx Revenue Rises 10% in 2025, Eyes Expanded Market with BENEFIT-HF Trial
Event summary
- CVRx reported $56.7M in total revenue for 2025, up 10% YoY, with U.S. revenue growing 10% to $51.9M.
- Active implanting centers in the U.S. increased to 252, up from 223 in 2024.
- The BENEFIT-HF trial, expected to begin enrollment in Q2 2026, aims to expand the addressable market for Barostim therapy.
- CVRx amended its term loan agreement with Innovatus Capital Partners, increasing the facility by $50M to $100M.
- Gross margin improved to 85% in 2025, up from 84% in 2024, driven by higher average selling prices and manufacturing efficiencies.
The big picture
CVRx's 2025 financial results reflect steady growth in its neuromodulation solutions, particularly in the U.S. market. The initiation of the BENEFIT-HF trial represents a strategic pivot to expand its addressable market, potentially tripling the patient population eligible for Barostim therapy. The company's ability to sustain this momentum will depend on the success of the trial and its continued operational efficiency improvements.
What we're watching
- Trial Success
- Whether the BENEFIT-HF trial can successfully expand the indicated patient population for Barostim therapy.
- Market Penetration
- The pace at which CVRx can increase active implanting centers and revenue units in the U.S. and Europe.
- Financial Performance
- How CVRx will manage its net loss while investing in the BENEFIT-HF trial and expanding its commercial operations.
Related topics